Generic Name and Formulations:
Fluocinolone acetonide 0.19mg; implant for intravitreal inj.
Indications for ILUVIEN:
Diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids without a significant rise in intraocular pressure.
Give by intravitreal inj. See full labeling for administration.
Ocular or periocular infections. Glaucoma.
Monitor for increased intraocular pressure and endophthalmitis; may include check for perfusion of the optic nerve head immediately, tonometry within 30 mins, and biomicroscopy between 2–7 days post inj. Risk of secondary ocular infections (eg, bacterial, fungal, viral). History of ocular herpes simplex: not recommended. Risk of implant migration if absent or torn posterior capsule of the lens. Pregnancy (Cat.C). Nursing mothers.
Cataract development, increased intraocular pressure; injection-related effects (eg, endophthalmitis, eye inflammation, retinal detachments), others.
Single-use applicator—1 (w. needle)
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks